MRI-guided delivery of viral vectors

Methods in Molecular Biology

Volumn 1382, Issue , 2016, Pages 217-230

  Salegio, Ernesto A ^a   Bringas, John ^a   Bankiewicz, Krystof S ^a  

^a NONE

Author keywords

AAV; Gene therapy; MRI; Nonhuman primates; Preclinical

Indexed keywords

PARVOVIRUS VECTOR; VIRUS VECTOR;

DRUG INFUSION; HUMAN; MONITORING; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMATE; RODENT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS PARTICLE; ADMINISTRATION AND DOSAGE; ANIMAL; BRAIN; DEPENDOPARVOVIRUS; DEVICES; GENE THERAPY; GENE VECTOR; GENETICS; MACACA FASCICULARIS; PROCEDURES; RHESUS MONKEY; VIROLOGY;

ANIMALS; BRAIN; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; MACACA FASCICULARIS; MACACA MULATTA; MAGNETIC RESONANCE IMAGING;

EID: 84948823759     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3271-9_15     Document Type: Chapter

References (15)

1. Chen Y, Liu L (2012) Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 64(7):640–665
2. Salvatore MF, Ai Y, Fischer B et al (2006) Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 202(2):497–505
3. Marks WJ Jr, Ostrem JL, Verhagen L et al (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7(5):400–408.
4. Eberling JL, Kells AP, Pivirotto P et al (2009) Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 20(5):511–518
5. Bartus RT, Herzog CD, Chu Y et al (2011) Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson’s disease and nonhuman primate brains. Mov Disord 26(1):27–36
6. Marks WJ Jr, Bartus RT, Siffert J et al (2010) Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9(12):1164–1172
7. Richardson R, Gimenez F, Salegio EA et al (2011) T2-imaging in monitoring of intraparenchymal real-time convection enhanced delivery. Neurosurgery 69(1):154–163
8. Richardson RM, Kells AP, Martin AJ et al (2011) Novel platform for MRI-guided convectionenhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg 89(3):141–151
9. San Sebastian W, Richardson RM, Kells AP et al (2012) Safety and tolerability of magnetic resonance imaging-guided convectionenhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum Gene Ther 23(2):210–217
10. Salegio E, Kells AP, Richardson RM et al (2010) Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders. Hum Gene Ther 21:1–11
11. Hadaczek P, Kohutnicka M, Krauze MT et al (2006) Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 17(3):291–302
12. Yin D, Richardson R, Fiandaca M et al (2010) Cannula placement for effective convectionenhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J Neurosurg 113:240–248
13. Paxinos G, Huang X, Petrides M, Toga A (2008) The rhesus monkey brain. Elsevier Inc, USA
14. Yin D, Forsayeth J, Bankiewicz K (2010) Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods 178:46–51
15. Krauze MT, Saito R, Noble C et al (2005) Refl ux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 103(5):923–929